TY - JOUR
T1 - Standard operating procedure combined with comprehensive quality control system for multiple LC-MS platforms urinary proteomics
AU - Urine Test Sample Working Group
AU - Liu, Xiang
AU - Sun, Haidan
AU - Hou, Xinhang
AU - Sun, Jiameng
AU - Tang, Min
AU - Zhang, Yong Biao
AU - Zhang, Yongqian
AU - Sun, Wei
AU - Liu, Chao
AU - Zhao, Yinghua
AU - Chen, Lingsheng
AU - Luo, Ji
AU - Du, Xiaoxian
AU - Liu, Xianming
AU - Qi, Yingzi
AU - Huang, Min
AU - Zhu, Wenyuan
AU - Hu, Weiyi
AU - Ji, Jianguo
AU - Chen, Yongsheng
AU - Zhang, Qing
AU - Guo, Liman
AU - Xue, Peng
AU - Tan, Minjie
AU - Tian, Ye
AU - Hu, Mo
AU - Wang, Guanbo
AU - Qiu, Xindan
AU - Zhang, Qi
AU - Liu, Dong
AU - Liu, Xinxin
AU - Yuan, Huiming
AU - Zhang, Lihua
AU - Sui, Xinying
AU - Wang, Guibin
AU - Li, Yanchang
AU - Tang, Xiaoyue
AU - Wu, Jianqiang
AU - Wei, Jing
AU - Jia, Lulu
AU - Liu, Kehui
AU - Shen, Ziyun
AU - Tang, Shuxuan
AU - Gao, Youhe
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography−mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms. To systematically analyze and assess the quality of large-scale urinary proteomics data, we develop a comprehensive quality control (QC) system named MSCohort, which extracted 81 metrics for individual experiment and the whole cohort quality evaluation. Additionally, we present a standard operating procedure (SOP) for high-throughput urinary proteome analysis based on MSCohort QC system. Our study involves 20 LC-MS platforms and reveals that, when combined with a comprehensive QC system and a unified SOP, the data generated by data-independent acquisition (DIA) workflow in urine QC samples exhibit high robustness, sensitivity, and reproducibility across multiple LC-MS platforms. Furthermore, we apply this SOP to hybrid benchmarking samples and clinical colorectal cancer (CRC) urinary proteome including 527 experiments. Across three different LC-MS platforms, the analyses report high quantitative reproducibility and consistent disease patterns. This work lays the groundwork for large-scale clinical urinary proteomics studies spanning multiple platforms, paving the way for precision medicine research.
AB - Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography−mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms. To systematically analyze and assess the quality of large-scale urinary proteomics data, we develop a comprehensive quality control (QC) system named MSCohort, which extracted 81 metrics for individual experiment and the whole cohort quality evaluation. Additionally, we present a standard operating procedure (SOP) for high-throughput urinary proteome analysis based on MSCohort QC system. Our study involves 20 LC-MS platforms and reveals that, when combined with a comprehensive QC system and a unified SOP, the data generated by data-independent acquisition (DIA) workflow in urine QC samples exhibit high robustness, sensitivity, and reproducibility across multiple LC-MS platforms. Furthermore, we apply this SOP to hybrid benchmarking samples and clinical colorectal cancer (CRC) urinary proteome including 527 experiments. Across three different LC-MS platforms, the analyses report high quantitative reproducibility and consistent disease patterns. This work lays the groundwork for large-scale clinical urinary proteomics studies spanning multiple platforms, paving the way for precision medicine research.
UR - http://www.scopus.com/inward/record.url?scp=85217112956&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-56337-4
DO - 10.1038/s41467-025-56337-4
M3 - Article
C2 - 39865094
AN - SCOPUS:85217112956
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1051
ER -